Stay updated on SBRT+Nivolumab/Ipilimumab in RCC Clinical Trial
Sign up to get notified when there's something new on the SBRT+Nivolumab/Ipilimumab in RCC Clinical Trial page.

Latest updates to the SBRT+Nivolumab/Ipilimumab in RCC Clinical Trial page
- Check7 days agoChange DetectedThe page now displays the ClinicalTrials.gov record for the SBRT and nivolumab/ipilimumab kidney cancer study, including its study details, eligibility criteria, locations, and results information, instead of an access-denied error.SummaryDifference50%

- Check14 days agoChange DetectedThe site’s displayed revision changed from v3.7.2 to v3.8.0; the page still shows a 403 error instead of the study record.SummaryDifference0.2%

- Check27 days agoChange DetectedThe site footer revision identifier changed from v3.7.1 to v3.7.2 on the 403 error page.SummaryDifference0.2%

- Check35 days agoChange DetectedThe site revision identifier in the footer changes from v3.7.0 to v3.7.1; the page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check55 days agoChange DetectedThe page now displays a 403 Forbidden error, indicating access to the study record is blocked. The standard site chrome remains visible, but the actual content is inaccessible, signaling a access restriction rather than a change to the study information.SummaryDifference19%

- Check77 days agoChange DetectedRevision label updated from v3.6.5 to v3.6.6. This indicates a minor platform/update change and does not modify study content.SummaryDifference0.1%

Stay in the know with updates to SBRT+Nivolumab/Ipilimumab in RCC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the SBRT+Nivolumab/Ipilimumab in RCC Clinical Trial page.